List of Excipients in Branded Drug CYANOKIT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Meridian Medical Technologies Inc	CYANOKIT	hydroxocobalamin	11704-370	HYDROCHLORIC ACID
BTG INTERNATIONAL INC	CYANOKIT	hydroxocobalamin	50633-310	HYDROCHLORIC ACID

Cyanokit Excipient Strategy, Patent Position and Commercial Opportunities

Last updated: August 5, 2026

Cyanokit is an intravenous hydroxocobalamin product used for emergency treatment of known or suspected cyanide poisoning. Its commercial value is driven by emergency preparedness, hospital stockpiling, government procurement and low substitution tolerance rather than chronic prescription volume. The formulation is unusually simple: hydroxocobalamin powder with mannitol as the principal excipient, reconstituted before intravenous infusion.

The strongest commercial opportunities are in supply reliability, ready-to-use presentation, pediatric dosing, emergency-department logistics, global procurement and differentiated supporting products. The core formulation has limited apparent exclusivity protection, but regulatory, manufacturing, stability and emergency-use requirements create meaningful practical barriers.

What is Cyanokit and how is it formulated?

Cyanokit contains hydroxocobalamin, a cobalt-containing cobalamin derivative that binds cyanide to form cyanocobalamin. It is supplied as a sterile, dark-red lyophilized powder for intravenous administration.

Product attribute	Cyanokit profile
Active ingredient	Hydroxocobalamin
Emergency indication	Known or suspected cyanide poisoning
Adult dose	5 g intravenously
Repeat dose	Additional 5 g, based on severity and clinical response
Pediatric dose	70 mg/kg, up to 5 g; repeat dosing may be used
Dosage form	Sterile lyophilized powder
Reconstitution volume	200 mL of compatible diluent for a 5 g vial
Primary diluent	0.9% sodium chloride
Principal excipient	Mannitol
Administration	Intravenous infusion
FDA application	NDA 022041
Original U.S. approval	2006

The U.S. prescribing information identifies 5 g of hydroxocobalamin and 3.5 g of mannitol per vial. Hydrochloric acid may be used for pH adjustment. The product is supplied with a transfer device and intravenous administration set in the U.S. presentation. [1]

What excipients are used in Cyanokit?

Mannitol is the principal functional excipient. It supports the bulk properties of the lyophilized cake and assists reconstitution after manufacture. The product is not formulated with preservatives, surfactants or complex lipid systems.

Why mannitol is commercially important

Mannitol has several advantages in an emergency injectable product:

• It is widely available at pharmaceutical grade.
• It is compatible with lyophilized sterile-product manufacturing.
• It has a long history in parenteral formulations.
• It provides solid mass without introducing a complex excipient profile.
• It can support a stable, rapidly reconstituted cake.

The simple excipient composition reduces formulation-development complexity. It also narrows the opportunity for a competing product to claim meaningful clinical differentiation through excipient substitution alone.

Excipient-related handling risks

Hydroxocobalamin solutions are intensely red and can discolor skin, mucous membranes and infusion equipment. The product label warns of laboratory-test interference, hemodialysis-machine interference and compatibility problems with selected intravenous solutions and medications. [1]

The relevant commercial issue is not excipient toxicity. It is operational performance:

• rapid dissolution after reconstitution;
• acceptable particulate control;
• container-closure integrity;
• protection from light and moisture;
• consistent cake structure;
• reliable delivery of the full 5 g dose;
• compatibility with emergency infusion equipment.

A substitute formulation that uses a different bulking agent would need to demonstrate equivalent sterility, stability, reconstitution time, dose recovery and clinical usability.

What formulation patents protect Cyanokit?

The publicly visible regulatory record identifies the product as a hydroxocobalamin sterile powder for injection, but the commercial protection profile is not equivalent to that of a heavily patented specialty drug.

Protection category	Cyanokit assessment
Active ingredient	Hydroxocobalamin is an established chemical entity
Core excipient system	Simple mannitol-based lyophilized formulation
Delivery system	Conventional intravenous infusion
Device protection	Transfer device and administration components may have separate rights
Method of use	Cyanide-poisoning treatment claims may exist in historical patent portfolios
Manufacturing protection	Sterile lyophilization, filling and packaging know-how may remain important
Orange Book position	Requires current FDA Orange Book verification; no assumption of active listed patents should be made without a live record review
Biosimilar pathway	Not applicable; Cyanokit is a small-molecule chemical product

The main defensibility is likely to come from manufacturing controls, product-specific stability data, emergency procurement relationships and regulatory execution. A competitor does not need to reproduce every commercial component if it can obtain approval for a therapeutically equivalent hydroxocobalamin injection.

Are Cyanokit patents expired?

Hydroxocobalamin has been used medically for decades, and the underlying compound does not provide modern composition-of-matter exclusivity. Any historical patents covering a particular formulation, use or manufacturing method must be reviewed by jurisdiction and claim scope.

For commercial planning, the relevant question is whether an active patent is listed against NDA 022041 and whether a proposed generic or alternative product would practice a valid, unexpired claim. FDA Orange Book entries, USPTO records, patent-family data and litigation dockets should be reconciled before relying on a freedom-to-operate conclusion. [2,3]

What is the FDA regulatory status of Cyanokit?

The FDA approved Cyanokit under NDA 022041 for the treatment of known or suspected cyanide poisoning. The product’s clinical and regulatory profile is unusual because use is concentrated in rare, high-consequence emergencies rather than routine outpatient prescribing.

FDA labeling includes major warnings relating to:

• hypertension;
• renal injury and oxalate crystal formation;
• laboratory-test interference;
• hemodialysis-machine interference;
• red discoloration;
• possible allergic reactions;
• pregnancy and pediatric use.

Cyanokit received pediatric labeling through supplemental regulatory action, and the label provides weight-based dosing for children. [1]

What regulatory pathway would a competing product use?

A competing hydroxocobalamin injection would likely pursue an abbreviated new drug application if it could establish the required pharmaceutical equivalence and bioequivalence framework. The principal development issues would include:

• identical active ingredient strength;
• sterile powder presentation;
• reconstitution performance;
• infusion concentration;
• impurity profile;
• container-closure system;
• stability;
• microbiological quality;
• labeling and warning alignment.

A new formulation with a materially different excipient system or presentation could require a full NDA or a more complex regulatory strategy, particularly if it changes exposure, reconstitution, infusion performance or safety.

What is the Orange Book status of Cyanokit?

Cyanokit is associated with FDA NDA 022041. The commercial status of any patent protection depends on the current Orange Book listing and whether listed patents remain enforceable. Orange Book status should be treated separately from broader patent-family ownership.

Orange Book question	Commercial implication
Are patents listed against NDA 022041?	Determines whether a Paragraph IV notice may be required
Are listed patents expired?	May remove timing barriers but not regulatory requirements
Are patents use codes only?	A generic may seek a carve-out for protected indications
Is pediatric use listed?	May affect labeling strategy and litigation exposure
Are device or packaging patents listed?	May not block a non-identical competing presentation

A Paragraph IV challenge would be commercially credible only if the challenger identifies an unexpired, listed patent with claims that cover the proposed product or indication. An applicant could also pursue a Section VIII statement for method-of-use patents where the product label omits the protected use.

When does Cyanokit lose exclusivity?

Cyanokit’s regulatory exclusivity is substantially less important today than its operational position in the emergency antidote market. The original U.S. approval occurred in 2006. Any ordinary new-drug exclusivity associated with that approval has expired. Pediatric exclusivity, if granted for a particular supplemental action, would not create a current broad market barrier.

Exclusivity type	Likely status
Five-year new chemical entity exclusivity	Expired
Three-year clinical-investigation exclusivity	Expired for original approval
Pediatric exclusivity	Any historical period would have expired
Orphan-drug exclusivity	Must be assessed against the specific designation and approval history
Patent exclusivity	Depends on live, claim-specific patent records
Regulatory know-how	Continues through manufacturing and quality systems

Loss of statutory exclusivity does not guarantee rapid generic entry. Demand is episodic, inventory must be maintained before an event occurs, and hospitals may prioritize validated supply over small price differences.

What generic entry risks exist for Cyanokit?

Generic entry risk is real but may develop slowly. The product has an attractive target profile because its active ingredient and excipient composition are relatively simple. Countervailing factors include a small market, specialized sterile manufacturing and procurement complexity.

High-risk entry scenarios

1. A manufacturer launches a therapeutically equivalent hydroxocobalamin powder for injection with a lower acquisition cost.
2. A hospital-contracted supplier offers an equivalent product bundled with emergency antidote inventory management.
3. A government tender separates product approval from incumbent brand preference.
4. A regional manufacturer obtains approval in a market where Cyanokit supply is constrained.
5. A competitor markets a smaller vial or weight-based presentation that reduces wastage.

Barriers to entry

• low but unpredictable annual demand;
• need for sterile lyophilization capacity;
• limited tolerance for reconstitution failure;
• emergency procurement qualification;
• supply continuity expectations;
• post-market safety monitoring;
• need to manage red-coloration and laboratory interference in labeling;
• limited opportunity to recover development costs through routine volume.

The most credible generic strategy is a direct, equivalent product rather than a heavily differentiated reformulation.

What formulation opportunities exist around Cyanokit?

The best opportunities are likely to improve logistics rather than alter hydroxocobalamin pharmacology.

Ready-to-use or faster-reconstitution products

A ready-to-use liquid would reduce preparation time but introduce stability, oxidation, light sensitivity, container compatibility and shelf-life challenges. The product would need to maintain sterility and potency across transportation and emergency storage conditions.

A practical intermediate option is an improved reconstitution system:

• pre-attached transfer device;
• reduced handling steps;
• closed-system transfer;
• clear dose-recovery markings;
• optimized diluent packaging;
• compatibility-tested infusion tubing;
• automated reconstitution instructions.

Pediatric presentations

The current pediatric dose is weight-based. A 5 g vial can create wastage when treating small children. Commercial opportunities include:

• lower-strength vials;
• premeasured pediatric kits;
• weight-band packaging;
• emergency department dosing tools;
• hospital stocking configurations.

A lower-strength vial would need to overcome additional manufacturing, packaging and inventory costs.

Excipient substitution

Replacing mannitol with another bulking agent could support a patentable formulation only if it solves a defined technical problem, such as improved stability, faster reconstitution or reduced precipitation. The substitution would face a high evidentiary burden because the current excipient system is familiar and operationally accepted.

Potential candidates could include other lyophilization bulking agents, but each would require compatibility and stability testing. A formulation patent based solely on replacing mannitol may be vulnerable to obviousness challenges unless the replacement produces an unexpected result.

How strong is the Cyanokit patent estate?

The estate appears more defensible as a regulated emergency product than as a compound protected by broad, current patent rights.

Patent-strength factor	Assessment
Composition-of-matter protection	Weak or unavailable for the established active ingredient
Core formulation protection	Potentially narrow and claim-dependent
Method-of-use protection	Possible, but likely limited by prior medical use and expiration
Device protection	May support incremental barriers
Manufacturing know-how	Operationally important but difficult to enforce against independent development
Regulatory dataset	Useful for brand credibility, not a substitute for patent exclusivity
Supply-chain position	Stronger than formal IP in emergency procurement

A competitive diligence review should rank claims by remaining term, prosecution history, obviousness exposure, enablement, written description and relevance to the approved label.

Which companies are challenging Cyanokit?

No specific active Paragraph IV challenger or major Cyanokit patent litigation campaign should be assumed without a current FDA, PACER and patent-docket review. The likely competitive set includes:

• generic injectable manufacturers;
• contract manufacturers with sterile lyophilization capacity;
• emergency antidote suppliers;
• regional government-tender manufacturers;
• pharmaceutical companies with hydroxocobalamin manufacturing capability.

The absence of visible high-volume generic competition can reflect market economics rather than strong patent protection.

What licensing deals affect Cyanokit?

The product’s commercial history includes changes in ownership and commercialization arrangements, but licensing terms, territorial rights, minimum purchase commitments and royalty economics are not generally disclosed in public FDA labeling.

For transaction analysis, the important rights are:

• U.S. NDA ownership;
• global trademark ownership;
• manufacturing rights;
• government and military procurement rights;
• rights to device components;
• rights to historical clinical and stability data;
• sublicensing restrictions;
• change-of-control provisions.

A licensee with manufacturing rights but no regulatory ownership may remain dependent on the NDA holder for supplements, pharmacovigilance and label changes.

What is the commercial opportunity for Cyanokit excipients and supporting products?

The largest opportunity is not a new excipient sold independently. It is an integrated emergency-use package.

Opportunity	Value proposition	Main barrier
Improved mannitol-based lyophilized formulation	Faster reconstitution and better cake integrity	Equivalence and stability data
Closed reconstitution kit	Fewer preparation errors	Device validation
Pediatric vial	Less wastage and simpler dosing	Small market and added SKUs
Stockpile-management service	Expiry monitoring and replacement	Procurement contracts
Compatible infusion accessories	Reduced operational risk	Hospital standardization
Regional manufacturing license	Local supply security	Regulatory transfer and quality systems
Alternative diluent package	Better field deployment	Compatibility and stability
Dual-use emergency kit	Supports EMS, hospitals and military users	Procurement qualification

Government and institutional buyers may pay for supply assurance, validated shelf life and replenishment services. The commercial model can combine product sales with inventory-management contracts.

How does Cyanokit compare with competing cyanide antidotes?

Cyanokit is differentiated from sodium nitrite and sodium thiosulfate regimens because hydroxocobalamin does not induce methemoglobinemia. That distinction matters when the poisoning source may involve smoke inhalation, carbon monoxide exposure or uncertain toxicology.

Attribute	Hydroxocobalamin/Cyanokit	Sodium nitrite plus sodium thiosulfate
Mechanism	Cyanide binding	Methemoglobin formation plus sulfur donation
Methemoglobinemia	Not the intended mechanism	Expected with sodium nitrite
Main dosage form	Lyophilized IV powder	Injectable solutions
Reconstitution burden	Present	Product-dependent
Color interference	Significant red coloration	Different interference profile
Emergency positioning	Broad field and hospital use	Alternative antidote regimen
Differentiation opportunity	Speed, safety profile, kit design	Cost and availability

The competing products are not automatically interchangeable from a clinical or procurement perspective. Product selection depends on poisoning context, protocols and available antidote stock.

What generic launch scenarios could affect Cyanokit revenue?

The most likely launch sequence would begin with one or more institutional suppliers rather than a broad retail generic campaign.

Scenario 1: Direct hospital generic

A generic manufacturer matches the 5 g vial and sells through hospital purchasing organizations. Price erosion would be moderate if Cyanokit remains preferred for emergency readiness.

Scenario 2: Government-tender substitution

A public-health agency awards supply to the lowest qualified bidder. This creates the highest volume risk because tenders can replace brand demand across large stockpiles.

Scenario 3: Pediatric and field-use entrant

A competitor launches smaller vials or a simplified kit. The product could capture specialized demand without immediately replacing the incumbent 5 g product.

Scenario 4: Supply-constrained premium

The incumbent retains pricing power if competitors cannot guarantee shelf life, continuity or rapid replenishment. Emergency antidote buyers often value availability over nominal unit price.

Key Takeaways

• Cyanokit is a 5 g intravenous hydroxocobalamin lyophilized powder with mannitol as its principal excipient.
• The formulation is simple, which limits the scope for excipient-based differentiation but supports generic development.
• The core commercial barriers are sterile manufacturing, stability, emergency procurement and supply reliability.
• Original FDA exclusivity periods have expired; current patent protection must be confirmed through live Orange Book and patent records.
• Biosimilar risk is not relevant because Cyanokit is a small-molecule product.
• The strongest formulation opportunities involve faster reconstitution, closed transfer systems, pediatric dosing and field-ready packaging.
• Generic entry would likely begin through hospital or government procurement rather than retail substitution.
• Revenue exposure is concentrated in institutional, government, military and emergency-response channels; standalone product revenue is not separately disclosed by the sponsor.
• A formulation patent based only on mannitol replacement would likely require a demonstrable technical advantage.
• Product supply, device integration and stockpile management may provide more durable commercial value than the active ingredient patent estate.

FAQs

Is mannitol essential to Cyanokit performance?

Mannitol is the principal excipient in the labeled formulation, but a competing manufacturer could use another excipient if it demonstrates acceptable pharmaceutical quality, stability, reconstitution and clinical performance.

Can Cyanokit be reformulated as a prefilled syringe?

A prefilled syringe would face substantial stability, dose-volume, viscosity, light-protection and container-compatibility requirements. It would represent a new product-development and regulatory program rather than a simple packaging change.

Does Cyanokit have biosimilar competition?

No. Hydroxocobalamin is a chemically defined small molecule. Any competitor would generally pursue a generic or full drug-approval pathway, not the biosimilar pathway.

Could a smaller Cyanokit vial reduce hospital wastage?

Yes. A lower-strength vial could improve pediatric and low-dose economics, but it would add manufacturing, packaging, inventory and regulatory complexity.

What is the most attractive licensing opportunity around Cyanokit?

The strongest licensing targets are likely local manufacturing, government-tender rights, closed-system reconstitution devices and emergency inventory-management services rather than a license to the basic hydroxocobalamin molecule.

References

1. U.S. Food and Drug Administration. (2023). Cyanokit (hydroxocobalamin for injection) prescribing information. Recordati Rare Diseases, Inc.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Patent and Trademark Office. (2024). Patent Center. https://patentcenter.uspto.gov/

4. National Library of Medicine. (2024). DailyMed: Cyanokit hydroxocobalamin injection, powder, lyophilized, for solution. https://dailymed.nlm.nih.gov/dailymed/